1 completed, 1 recruiting, 1 suspended. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Suspended 1 |
Follow Stage III Small Intestinal Adenocarcinoma AJCC v8: new trials by email Literature Review of Stage III Small Intestinal Adenocarcinoma AJCC v8 trials Research Report on Stage III Small Intestinal Adenocarcinoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE - Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma | Phase 2 | Suspended | Thomas Jefferson University | 48 | 2020-11-10 | 2026-09-14 |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers Fluorouracil, Irinotecan, Irinotecan Hydrochloride - Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 94 | 2020-06-01 | 2026-10-23 |
| Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma Bevacizumab, Capecitabine, Oxaliplatin - Ampulla of Vater Adenocarcinoma, Small Intestinal Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2011-05-06 | 2020-09-03 |
Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Pancreatic Neoplasms (1)
Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Pancreatic Diseases (1) · Rectal Diseases (1)
Bevacizumab (1) · Capecitabine (1) · Disulfides (1) · Fluorouracil (1) · Immunoglobulin G (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Paclitaxel (1) · Ramucirumab (1) · Taxes (1) · dehydroftorafur (1)
M.D. Anderson Cancer Center (1) · SWOG Cancer Research Network (1) · Thomas Jefferson University (1)
United States (3)
Babar Bashir, MD (1) · Michael J Overman (1) · Michael Overman (1)
P30CA016672 (1), U10CA180888 (1)